LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Effects of long-term PPI treatment on producing bowel symptoms and SIBO.

    Compare, Debora / Pica, Loredana / Rocco, Alba / De Giorgi, Francesco / Cuomo, Rosario / Sarnelli, Giovanni / Romano, Marco / Nardone, Gerardo

    European journal of clinical investigation

    2011  Volume 41, Issue 4, Page(s) 380–386

    Abstract: Background: Gastroesophageal reflux disease (GERD), including erosive reflux disease and non-erosive reflux disease (NERD), is a chronic disease with a significant negative effect on quality of life. State-of-the-art treatment involves proton pump ... ...

    Abstract Background: Gastroesophageal reflux disease (GERD), including erosive reflux disease and non-erosive reflux disease (NERD), is a chronic disease with a significant negative effect on quality of life. State-of-the-art treatment involves proton pump inhibitors (PPIs). However, relapse of symptoms occurs in the majority of the patients who require recurrent or continuous therapy. Although PPIs are well tolerated, little information is available about gastrointestinal side effects.
    Aim: To evaluate the effects of long-term PPI treatment on development of bowel symptoms and/or small intestinal bacterial overgrowth (SIBO).
    Methods: Patients with NERD not complaining of bowel symptoms were selected by upper endoscopy, 24-h pH-metry and a structured questionnaire concerning severity and frequency of bloating, flatulence, abdominal pain, diarrhoea and constipation. Patients were treated with esomeprazole 20 mg bid for 6 months. Prior to and after 8 weeks and 6 months of therapy, patients received the structured questionnaire and underwent evaluation of SIBO by glucose hydrogen breath test (GHBT).
    Results: Forty-two patients with NERD were selected out of 554 eligible patients. After 8 weeks of PPI treatment, patients complained of bloating, flatulence, abdominal pain and diarrhoea in 43%, 17%, 7% and 2%, respectively. After 6 months, the incidence of bowel symptoms further increased and GHBT was found positive in 11/42 (26%) patients. By a post hoc analysis, a significant (P < 0·05) percentage of patients (8/42) met Rome III criteria for irritable bowel syndrome.
    Conclusions: Prolonged PPI treatment may produce bowel symptoms and SIBO; therefore, the strategy of step-down or on-demand PPI therapy should be encouraged in GERD.
    MeSH term(s) Adult ; Esomeprazole/adverse effects ; Female ; Gastroesophageal Reflux/drug therapy ; Gastroesophageal Reflux/physiopathology ; Humans ; Intestines/drug effects ; Intestines/microbiology ; Irritable Bowel Syndrome/chemically induced ; Irritable Bowel Syndrome/physiopathology ; Italy ; Male ; Middle Aged ; Proton Pump Inhibitors/adverse effects ; Time Factors
    Chemical Substances Proton Pump Inhibitors ; Esomeprazole (N3PA6559FT)
    Language English
    Publishing date 2011-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 186196-7
    ISSN 1365-2362 ; 0014-2972 ; 0960-135X
    ISSN (online) 1365-2362
    ISSN 0014-2972 ; 0960-135X
    DOI 10.1111/j.1365-2362.2010.02419.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Is screening for and surveillance of atrophic gastritis advisable?

    Nardone, Gerardo / Rocco, Alba / Compare, Debora / De Colibus, Patrizia / Autiero, Giovanni / Pica, Loredana / de Nucci, Germana / Gasbarrini, Giovanni

    Digestive diseases (Basel, Switzerland)

    2007  Volume 25, Issue 3, Page(s) 214–217

    Abstract: Gastric cancer remains a leading cause of cancer-related deaths in many parts of the world. At present, prevention seems to be the most effective means to reduce its the incidence and mortality rate. Gastric atrophy is considered the first relevant step ... ...

    Abstract Gastric cancer remains a leading cause of cancer-related deaths in many parts of the world. At present, prevention seems to be the most effective means to reduce its the incidence and mortality rate. Gastric atrophy is considered the first relevant step in the histogenesis of gastric adenocarcinoma. However, whether screening for and surveillance of atrophic gastritis is advisable is debated. The prevalence and pattern of chronic atrophic gastritis varies greatly from country to country, being higher and mainly diffuse pangastritis or localized in those countries with a high gastric cancer incidence. The only method available to detect gastric atrophy is histopathological examination of endoscopic specimens, but there is no consensus about diagnosis. Serum gastric secretion may be a marker of gastric atrophy, although it has high specificity but low sensitivity. Gastric atrophy is mainly related to chronic Helicobacter pylori (H. pylori) infection. Thus, the only effective strategy for gastric cancer prevention is eradication of H. pylori infection to arrest atrophy progression in selected populations. In conclusion, there is insufficient evidence to suggest screening for and surveillance of atrophic gastritis in the general population; however, this strategy should be applied in countries with a high incidence of gastric cancer.
    MeSH term(s) Adenocarcinoma/prevention & control ; Gastritis, Atrophic/diagnosis ; Gastritis, Atrophic/therapy ; Humans ; Mass Screening ; Population Surveillance ; Stomach Neoplasms/prevention & control
    Language English
    Publishing date 2007
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 632798-9
    ISSN 1421-9875 ; 0257-2753
    ISSN (online) 1421-9875
    ISSN 0257-2753
    DOI 10.1159/000103887
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Large Brunner's gland adenoma: case report and literature review.

    Rocco, Alba / Borriello, Pasquale / Compare, Debora / De Colibus, Patrizia / Pica, Loredana / Iacono, Alessandro / Nardone, Gerardo

    World journal of gastroenterology

    2006  Volume 12, Issue 12, Page(s) 1966–1968

    Abstract: Brunner's gland adenoma (BGA) is a very rare benign tumour of the duodenum, which is usually asymptomatic and discovered incidentally at endoscopy. Occasionally, this lesion may be large, causing upper gastrointestinal haemorrhage or intestinal ... ...

    Abstract Brunner's gland adenoma (BGA) is a very rare benign tumour of the duodenum, which is usually asymptomatic and discovered incidentally at endoscopy. Occasionally, this lesion may be large, causing upper gastrointestinal haemorrhage or intestinal obstruction. The case had a large Brunner's gland adenoma, presenting melena that was managed by endoscopic excision.
    MeSH term(s) Adenoma/diagnosis ; Adenoma/pathology ; Adenoma/surgery ; Brunner Glands/pathology ; Brunner Glands/surgery ; Duodenal Neoplasms/diagnosis ; Duodenal Neoplasms/pathology ; Duodenal Neoplasms/surgery ; Endoscopy ; Female ; Humans ; Middle Aged
    Language English
    Publishing date 2006-01-28
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v12.i12.1966
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Is Screening for and Surveillance of Atrophic Gastritis Advisable?

    Nardone, Gerardo / Rocco, Alba / Compare, Debora / De Colibus, Patrizia / Autiero, Giovanni / Pica, Loredana / De Nucci, Germana / Gasbarrini, Giovanni

    Digestive Diseases

    2007  Volume 25, Issue 3, Page(s) 214–217

    Abstract: Gastric cancer remains a leading cause of cancer-related deaths in many parts of the world. At present, prevention seems to be the most effective means to reduce its the incidence and mortality rate. Gastric atrophy is considered the first relevant step ... ...

    Institution Department of Clinical and Experimental Medicine, Gastroenterology Unit, University ‘Federico II, Naples, and Institute of Internal Medicine, Catholic University, Rome, Italy
    Abstract Gastric cancer remains a leading cause of cancer-related deaths in many parts of the world. At present, prevention seems to be the most effective means to reduce its the incidence and mortality rate. Gastric atrophy is considered the first relevant step in the histogenesis of gastric adenocarcinoma. However, whether screening for and surveillance of atrophic gastritis is advisable is debated. The prevalence and pattern of chronic atrophic gastritis varies greatly from country to country, being higher and mainly diffuse pangastritis or localized in those countries with a high gastric cancer incidence. The only method available to detect gastric atrophy is histopathological examination of endoscopic specimens, but there is no consensus about diagnosis. Serum gastric secretion may be a marker of gastric atrophy, although it has high specificity but low sensitivity. Gastric atrophy is mainly related to chronic Helicobacter pylori (H. pylori) infection. Thus, the only effective strategy for gastric cancer prevention is eradication of H. pylori infection to arrest atrophy progression in selected populations. In conclusion, there is insufficient evidence to suggest screening for and surveillance of atrophic gastritis in the general population; however, this strategy should be applied in countries with a high incidence of gastric cancer.
    Keywords Gastric cancer ; Atrophic gastritis, surveillance ; Atrophic gastritis, screening
    Language English
    Publishing date 2007-09-10
    Publisher S. Karger AG
    Publishing place Basel, Switzerland
    Document type Article
    Note Stomach
    ZDB-ID 632798-9
    ISBN 978-3-8055-8333-6 ; 978-3-318-01487-7 ; 3-8055-8333-8 ; 3-318-01487-7
    ISSN 1421-9875 ; 0257-2753
    ISSN (online) 1421-9875
    ISSN 0257-2753
    DOI 10.1159/000103887
    Database Karger publisher's database

    More links

    Kategorien

To top